The work underpinned an Alzheimer's drug by Cassava, now in a Phase III trial.

A federal grand jury has indicted an embattled Alzheimer’s researcher for allegedly falsifying data to fraudulently obtain $16 million in federal research funding from the National Institutes of Health for the development of a controversial Alzheimer’s drug and diagnostic test.

Hoau-Yan Wang, 67, a medical professor at the City University of New York, was a paid collaborator with the Austin, Texas-based pharmaceutical company Cassava Sciences. Wang’s research and publications provided scientific underpinnings for Cassava’s Alzheimer’s treatment, Simufilam, which is now in Phase III trials.

  • ToucheGoodSir@lemy.lol
    12·
    3 days ago

    Feel there is too much pressure on researchers to produce results that are profitable vs what scientists are passionate about doing science on. As always, ALWAYS GOTTA THINK ABOUT THEM QUARTERLY PROFITS @_@

    • RBG@discuss.tchncs.de
      6·
      3 days ago

      That is not even it. It is about finding that novel thing that will lead research direction of a certain topic for years to come. To be THE expert that found THAT thing that could finally cure Alzheimer’s. Not denying for some it is not also about money.